T1	Participants 225 274	patients with metastatic colorectal cancer (mCRC)
T2	Participants 571 674	279 previously untreated mCRC patients treated with capecitabine, oxaliplatin and bevacizumab (CAPOX-B)
T3	Participants 1469 1482	mCRC patients
